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Response to Letter to the Editor
Sir,
Ubbink et al. have published a systematic review on nega-
tive pressure wound therapy in the British Journal of
Surgery in the beginning of 2008 along with a double
publication in the Cochrane Library. They consider that our
paper later in 2008 in the European Journal of Vascular
Surgery poses a double publication of their work as the
original trials are very much the same.
We consider the points raised by Ubbink et al. unjus-
tified, unscientific and unethical. Objectivity and repeat-
ability of the findings is a fundamental principle in science
and this principle encompasses both original studies and
systematic reviews. We found ten previous systematic
reviews published on negative pressure wound therapy,DOI of original article: 10.1016/j.ejvs.2009.01.018.the review by Ubbink et al. being one of those reviews.
We have referred to these publications in our paper. The
need for new reviews is based not only on repeatability
of findings but on different study questions in the
previous reviews and in other differences in the review
protocols.
The suggestion of a double publication is entirely
groundless. We did plan our study protocol already in 2006
and our data for the meta-analysis was collected by an
informatician at the Finnish Office for Health Technology
Assessment in July 2006 and the search was revisited in
January 2008 as stated in our materials and methods. Our
first submission to EJVES was dated in March 31st, 2008 and
our final revision was submitted in June 3rd, 2008. Thus our
paper was entirely independent of the work by Ubbink
et al. We find it extraordinary that Ubbink et al. consider
that we should not have had the right to publish our paper.
We think that this is unjustified and violates the principles
of scientific publication.1
Redundant or duplicate publication is considered when
the same data is used to generate several publications and
most often when the same author or group reports their
data in different papers. Ubbink et al. refer to an editorial
by Murie et al., in which a case of redundant publication on
a series of laparoscopic cholecystectomy complications is
discussed. In this case the two original publications
included overlapping cases and the authors discussed this
being due to changes during the peer-review process. This
discussion should not be confused with the current one
where there were two entirely separate scientific
publications.
The efficacy, effectiveness and safety of negative pres-
sure wound therapy is and continues to be of high relevance
as the technology diffuses rapidly into the health care
without sufficient evidence of its effectiveness, but a high
level of economical interests. Further trials have been and
will be published on negative pressure wound therapy in
the coming years and we hope that the body of evidence
will grow.
We look forward to new systematic reviews on this
important topic.Reference
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Response to Letter to the Editor re: Outcome of
Endovenous Laser Therapy for Saphenous Reflux and
Varicose Veins: Medium - Term Results Assessed by
Ultrasound
Drs. Ghosh and Baguneid agree with our conclusion that ‘‘It
may well be that success rates will improve with increasing
power .’’, although multivariate analysis showed no rela-
tion between power and outcome. However, the references
quoted provide little assistance. Mordon et al.1 studied
a mechanical model and reported that ‘‘for a 3 mm vein
diameter. for 10 W and 2 mm/s pullback speed.
a minimum of 100 J/cm.,’’ and that ‘‘for a 5 mm vein
diameter. for 15 W and 2 mm/s pullback speed.
a minimum of 150 J/cm.’’ is required to damage the vessel
wall. Theivacumar et al.2 reported median energy density of
48 J cm1 in limbs with complete occlusion and 37 J cm1 in
those with partial occlusion; it is unlikely that these would
differ significantly from the median 44 J cm1 reported in
our study. The techniques in both references differed from
ours and, therefore, comparisons cannot be made.
Prince et al. reported no difference for early re-canal-
isation rates for energy ranging from <60 J cm1 to
>100 J cm1,3 whereas Vuylsteke et al. reported a signifi-
cantly higher mean fluence for veins that remained occluded
than for those that failed early.4 Proebsle et al. reported that
low fluence increased risk for early failure,5 and that
patients treated with 30 W had better medium-term results
than for those treated with 15 W.6 These studies also used
techniques other than those used in our report.
The effect of laser energy is dependent on wavelength,
power, probe-withdrawal rate and whether energy is contin-
uous or pulsed. Commercial systems use wavelengths from
810 nm to 1500 nm. Planck’s formula indicates that energy is
proportional to frequency so that higher wavelengths require
more exposure time. Published reports use either continuous
orpulsedpowerat various levels to15 W.WeagreewithGhosh
and Baguneid that determining best protocols to provide
highest long-term occlusion rates with least patient discom-
fort requires randomisation for these variables with long-term
surveillance, and we thank them for stimulating discussions.
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Plaque Biology, Realizing the Clinical Potential
In their carotid masterclass, Loftus and Thompson address
the question if plaque biology is interesting science or
a pharmacological treasure trove, concluding that it is more
of the former than the latter.1
Recent data suggest that carotid plaque phenotype in fact
may be the major independent determinant of the degree of
benefit of carotid endarterectomy. Carotid plaque composi-
tion is closely related to clinical presentation,2,3 gender,4 age5
andtime intervalbetweenmost recent ischemic symptomsand
CEA.6,7 We think it is no co-incidence that these clinical char-
acteristics are also the major determinants of CEA benefit,8
because theyare all associated with plaque composition that is
thought to portray an increased stroke risk if untreated, i.e. an
inflamed plaque with a large lipid pool and a thin fibrous cap.9
There is strong accumulating evidence from descriptive
and now also longitudinal studies that specific plaque
composition is related with adverse outcome following CEA.
Recently the Athero-Express study reported that plaque
composition is a strong independent predictor of restenosis
following CEA.10
Considering these recent data, we feel the question
should not be if plaque composition is relevant, but rather
how soon we will be able to include measurements of
plaque composition in decision making in clinical practice.DOI of original article: 10.1016/j.ejvs.2008.06.002.
